Fasoracetam
mGluR I/II/III modulator racetam, ADHD clinical research.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS FASORACETAM?
Detailed overview
Fasoracetam (NS-105 / LAM-105 / NFC-1) is originally a Nippon Shinyaku (Japan) development that acts via up-regulation of metabotropic glutamate receptors (mGluR I/II/III). Aevi Medical (formerly Medgenics) advanced it to Phase 2/3 in ADHD (mGluR-mutation-positive adolescents) – initially positive, then mixed results in the 2019 expanded ADHD trial (PMID 31167583). Unique: upregulates GABA-B receptor expression (PMID 10494996) – anecdotally used to support Phenibut withdrawal. Cholinergic HACU enhancement (Coluracetam-like but weaker). cAMP→BDNF signaling cascade for memory formation. Banned in the UK under the Psychoactive Substances Act (since 2016).
Mechanism
mGluR I/II/III up-regulation
Half-life
~5-8 h
Legal status
Investigational, clinical trials
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Headache, often from increased cholinergic activity (mitigated with a choline source such as CDP-choline)
- Abdominal pain, diarrhea and nausea, mainly at doses above the nootropic range
- Fatigue, lethargy
- Irritability
- Dizziness, mild lightheadedness, especially when starting use
Contraindications · 5
- Pregnancy and breastfeeding: no safety data, should be avoided
- Combined with phenibut or other GABA-B-active agents it potentiates their effect (GABA-B upregulation), caution required
- Prolonged high-dose use may burden liver and kidney function, caution with long-term use
- Clinical-trial-stage compound, not approved anywhere, long-term safety unknown
- Not recommended under 18; those on medication or with serious medical conditions should seek medical advice first
Related Nootropics
Same therapeutic category
Telegram
Have a question about Fasoracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.